Medically reviewed by Christopher Lee, MD Treatment for ATTR-CM has historically been symptom management. However, until 2019, the United States Food and Drug Administration (FDA) did not approve any ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $357.7, a high estimate of $404.00, and a low estimate of $325.00. Marking an increase of 10.61%, the ...

Alnylam (Nasdaq: ALNY) has secured expanded UK regulatory approval for Amvuttra (vutrisiran), broadening its indication to include treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults ...

On March 20, 2025, Alnylam received approval from the U.S. Food and Drug Administration (FDA) for Amvuttra to treat ATTR-CM. The approval came with a broad label that includes language about reducing ...

Additionally, Alnylam reiterated its 2025 total product revenue guidance of $2.05-2.25 billion during a recent meeting with Needham, which raised its price target for Alnylam to $377.00, maintaining a ...

Needham updated its Amvuttra revenue model and raised its out-year ATTR revenue estimates as a result of the meeting. The company’s overall revenue growth stands at 17.21%, with InvestingPro data ...

Alnylam Pharmaceuticals specializes in RNA interference therapeutics, with Amvuttra being one of its key products targeting transthyretin-mediated amyloidosis, a rare and often fatal disease that can ...